Clinical trial

Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients

NCT01897051

Study summary

ClinicalTrials.gov

Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Rifaximin + propranolol Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Propranolol + Placebo Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2013-07-01

PhasePHASE2 / PHASE3

Conditions

Liver Cirrhosisunresolved

Portal Hypertensionverified · MONDO: portal hypertension

Interventions

Rifaximin + propranololDRUG

Propranolol + PlaceboDRUG

Sponsors & collaborators

Yonsei Universitylead sponsor

Mapped research locations

WŏnjuSouth Korea1 WŏnjuGangwon-do, South Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01897051 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.